Takeda reports positive Phase 2/3 trial results for TAK-881 in immune disorder
Tweet Send to a Friend
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE: TAK) announced that its investigational treatment TAK-881 met the primary endpoint in a pivotal Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
